Enalapril

Enalapril

SCHEMBL13575793

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ACE known ✓ P12821 14/20 1.00
LMNA P02545 2/20 1.00
SMN1; SMN2 Q16637 1/20 0.91
ABCB11 O95342 2/20 0.70
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
USP2 O75604 1/20 0.68
CYP3A4 P08684 1/20 0.68
ALOX15 P16050 1/20 0.68
PDE3A Q14432 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enalapril SCHEMBL28322902 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL678442 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL8089096 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL13933092 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL18 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL6159149 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL97 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL474012 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL8433334 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1
Enalapril SCHEMBL28323975 1.00 ACE (1.00) ACELMNASMN1; SMN2ABCB11MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394813-B2 Active agent delivery systems and methods for protecting and administering active agents SHIRE LLC (US) 2013-03-12 US disclosed
US-20090306228-A1 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS SHIRE LLC (US) 2009-12-10 US disclosed
US-20090253792-A1 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS SHIRE LLC (US) 2009-10-08 US disclosed
US-7427600-B2 Active agent delivery systems and methods for protecting and administering active agents SHIRE LLC (US) 2008-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253792-A1 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS HDGF, CTSA, IAPP ACE 504/4885LMNA 760/4885SMN1; SMN2 629/4885
US-20090306228-A1 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS HDGF, CTSA, IAPP ACE 504/4885LMNA 760/4885SMN1; SMN2 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.